Journal Article Summary
The article investigates the use of semaglutide, a medication typically used for weight management, in individuals with schizophrenia or schizoaffective disorder who are also dealing with obesity. This topic is significant because many people with severe mental illnesses experience weight gain, which can lead to serious health issues such as diabetes and cardiovascular disease. By exploring the feasibility and acceptability of semaglutide in a psychiatric inpatient setting, the study aims to address a pressing health concern for this vulnerable population.
In this study, 15 patients diagnosed with schizophrenia or schizoaffective disorder and having a body mass index (BMI) of at least 30 kg/m² were treated with weekly semaglutide injections over a period of up to six months. The results showed that most participants experienced weight loss, with an average reduction in BMI and improvements in blood sugar levels (HbA1c). Additionally, patients reported better quality of life scores after treatment, indicating that semaglutide may have positive effects beyond weight loss. However, some patients discontinued the treatment due to side effects or lack of funding for continued use after discharge.
Despite the promising findings, the study has limitations, including a small sample size and a short duration of follow-up. Not all participants remained on semaglutide for the entire study period, and the lack of funding for outpatient treatment raises concerns about accessibility. Patients and caregivers should discuss these findings with healthcare professionals, particularly regarding the potential benefits and risks of semaglutide, as well as the importance of ongoing support for weight management in individuals with severe mental illness.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Heald Adrian H., Reynolds Gavin, Nash Isabel, Boyle Onagh, Daly Chris, Longson Damien, O’Shea Donal, Ingram Joseph, et al.. Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss. Advances in Therapy 2025. DOI: 10.1007/s12325-025-03261-0. PMID: 40536760. PMCID: PMC12313766.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
